
    
      This is a study in healthy participants with Helicobacter pylori (HP positive) to evaluate
      the safety, tolerability and PK of a quadruple therapy with bismuth, clarithromycin,
      amoxicillin, and vonoprazan versus quadruple therapy with bismuth, clarithromycin,
      amoxicillin, and esomeprazole. The study will enroll approximately 34 participants.

      The treatment phase consists of quadruple therapy twice daily (BID) with bismuth potassium
      citrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and vonoprazan (20 mg)
      (Group B) or quadruple therapy BID with bismuth potassium citrate (600 mg), clarithromycin
      (500 mg), amoxicillin (1000 mg), and esomeprazole (20 mg) (Group A) from Days 1 to 14.
      Participants will be discharged on Day 15 after final PK blood samples are collected and all
      procedures performed.

      This single-center will be conducted in China. Participants will remain confined to the study
      site from check-in (Day -1) through Day 15 and will followed up through call on Day 17 and
      return on Day 42 for a follow-up assessment.
    
  